ArticleFrontiers in oncology2025
Comparison of micro-flow imaging and contrast-enhanced ultrasound in monitoring microwave ablation of papillary thyroid carcinoma: efficacy, safety, and cost-effectiveness.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the value of micro-flow imaging (MFI) in monitoring ultrasound-guided microwave ablation (MWA) of papillary thyroid carcinoma (PTC) by comparing it with contrast-enhanced ultrasound (CEUS). Methods: This study was conducted on 83 malignant nodules from 79 papillary thyroid carcinoma (PTC) patients treated between June 2022 and September 2023. These cases were divided into a control group (n=37) and an observation group (n=42) based on different guidance modalities during microwave ablation (MWA). The observation group underwent MFI monitoring, while the control group received CEUS monitoring. Clinical parameters were systematically compared between groups, including: 1) baseline clinical characteristics, 2) two-dimensional ultrasound features, 3) vascular patterns (MFI/CEUS), 4) tumor volume (V), 5) volume reduction rate (VRR), 6) postoperative complications, and 7) patient satisfaction outcomes. Results: All patients successfully underwent ablation. During multiple follow-ups post-MWA, no local recurrence or distant metastasis was observed in either group, and changes in V and VRR were similar (p > 0.05). Consistency was also observed in the number of ablations, ablation time, and postoperative complications between the two groups (p > 0.05). However, the MFI group had lower treatment costs and operation time compared to the CEUS group (p < 0.05), and patients in the MFI group reported higher satisfaction with the procedure (p < 0.05). Conclusion: The effectiveness and safety of MFI monitoring during PTC ablation are similar to those of CEUS, with the added advantages of lower costs and greater patient satisfaction, making MFI a preferable option for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.